Recent Updates
Recently added Catalysts

furmonertinib , daily

Phase 3

Metastatic Non-Small Cell Lung Cancer | Small molecule | Oncology |ArriVent BioPharma, Inc.|Last Updated: Jun 22, 2025

Success Probability
Subscribe to view
Market & Valuation
Subscribe to view
Trial Design
RandomizedACTIVE_CONTROLLEDDMC
Total Trials1
Total Enrollment398
FDA Designations
BREAKTHROUGH_THERAPY
Clinical trial landscape

furmonertinib , daily · 1 trial · 3 indications

Phase 3 1
NCT05607550Study to Compare Furmonertinib to Platinum-Based Chemotherapy for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations (FURVENT)Metastatic Non-Small Cell Lung Cancer
ACTIVE NOT_RECRUITING398 Analytics
PHASE3ACTIVE NOT_RECRUITING
Study to Compare Furmonertinib to Platinum-Based Chemotherapy for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations (FURVENT)
Metastatic Non-Small Cell Lung Cancer
NCT05607550398
Unlock trial analytics
Study Endpoints
Primary Endpoints
Progression Free Survival (PFS) determined by blinded independent central review (BICR)
Up to 32 months after first dose
Secondary Endpoints
Overall Survival (OS)
Up to 62 months after first dose
PFS determined by investigator assessment
Up to 36 months after first dose
Overall response rate (ORR)
Up to 36 months after first dose
Unlock Study Endpoints
Study Design & Arms
AllocationRANDOMIZED
MaskingNONE
ModelPARALLEL
PurposeTREATMENT
Treatment Arms
ArmTypeDescription
furmonertinib 240 mgEXPERIMENTAL -
furmonertinib 160 mgEXPERIMENTAL -
platinum-based chemotherapyACTIVE_COMPARATORcarboplatin or cisplatin based on investigator's choice + pemetrexed intravenously
Interventions
NameTypeDescription
furmonertinib 240 mg oral, dailyDRUGfurmonertinib tablet
furmonertinib 160 mg oral, dailyDRUGfurmonertinib tablet
platinum-based chemotherapyDRUG(carboplatin or cisplatin based on investigator's choice) + pemetrexed intravenously (IV)
Unlock Study Design Details
Eligibility Criteria
Age Range18 Years to N/A
SexALL
Healthy VolunteersNo
Study Sites208

Key Inclusion Criteria: * Histologically or cytologically documented, locally advanced or metastatic non-squamous Non-Small Cell Lung Cancer (NSCLC) not amenable to curative surgery or radiotherapy. * Documented results of the presence of an Epidermal Growth Factor Receptor (EGFR) exon 20 insertion...

Countries:United StatesAustraliaBrazilCanadaChinaFranceIsraelItalyJapanMalaysiaMexicoNetherlandsPhilippinesSingaporeSouth KoreaSpainTaiwanThailandUnited Kingdom
Unlock Eligibility Criteria
Competitive Landscape -Non-Small Cell Lung Cancer 395 trials (matched to "Metastatic Non-Small Cell Lung Cancer")

Top 20 of 86 competitors

CompanyTickerTrialsLead PhaseDrugs
Merck & Co., Inc.MRK25PHASE3Pembrolizumab, Olaparib, Etoposide, Carboplatin, Cisplatin
AstraZeneca PLCAZN62PHASE3Datopotamab deruxtecan, Durvalumab, Carboplatin, Pembrolizumab, Cisplatin
Revolution Medicines, Inc.RVMD8PHASE3daraxonrasib, docetaxel
Eli Lilly and CompanyLLY19PHASE3Selpercatinib, Carboplatin, Cisplatin, Pemetrexed, Pembrolizumab
AbbVie, Inc.ABBV10PHASE3Telisotuzumab Vedotin, Docetaxel
Amgen Inc.AMGN5PHASE3AMG 510, Docetaxel
Bristol-Myers Squibb CompanyBMY19PHASE3Repotrectinib, Crizotinib
BioNTech SE Sponsored ADRBNTX7PHASE3Gotistobart, Docetaxel
Gilead Sciences, Inc.GILD4PHASE3Sacituzumab Govitecan-hziy, Docetaxel
Johnson & JohnsonJNJ17PHASE3Lazertinib, Amivantamab, Pemetrexed, Carboplatin
ArriVent BioPharma, Inc.AVBP9PHASE3Firmonertinib
Pfizer Inc.PFE17PHASE3Lorlatinib, Crizotinib
GSK plc Sponsored ADRGSK4PHASE3Dostarlimab, Belrestotug, Pembrolizumab
Novartis AG Sponsored ADRNVS9PHASE3JDQ443, docetaxel
Summit Therapeutics IncSMMT2PHASE3Ivonescimab, Pembrolizumab
Nuvation Bio, Inc. Class ANUVB4PHASE3Taletrectinib, Crizotinib
Genmab A/S Sponsored ADRGMAB4PHASE3Acasunlimab, Pembrolizumab, Docetaxel
Regeneron Pharmaceuticals, Inc.REGN6PHASE2cemiplimab, Platinum Doublet, fianlimab
BeOne Medicines Ltd. Sponsored ADRONC6PHASE3Tislelizumab, Cisplatin, Paclitaxel, Pemetrexed Disodium, Carboplatin
BeyondSpring Inc.BYSI1PHASE3Plinabulin, Docetaxel
Unlock Competitive Intelligence
Recent Changes (Last 90 Days)
LOWMay 26, 2026NCT05607550primaryCompletionDate: changed
LOWMay 24, 2026NCT05607550studyFirstPostDate: changed